# Glioblastoma & Brain Tumours Boswellia is one of the most clinically developed natural compounds in **glioblastoma and brain tumour support**, largely because of its effect on radiation-induced cerebral oedema. ### Why this page matters This is Boswellia's strongest current oncology niche. The reason is not only anticancer theory. It is the combination of: * human data for **radiation-related cerebral oedema** * meaningful **steroid-sparing relevance** * preclinical evidence for **glioblastoma growth inhibition** * plausible **radiosensitising** biology ### Human evidence — radiation-related cerebral oedema The most important human dataset is the **Kirste pilot randomised trial** in brain-tumour patients receiving radiotherapy. Key points: * the study was **prospective, randomised, placebo-controlled, and double-blind** * the Boswellia arm used **4,200 mg/day** in divided doses * MRI-assessed **cerebral oedema fell more** in the Boswellia group than in the placebo group * some patients also showed **neurologic improvement** and reduced steroid pressure * the **4,200 mg/day** regimen was reported as well tolerated This matters because it moves Boswellia beyond theory. It gives a real human dosing anchor in active neuro-oncology care. ### Radiation necrosis and later clinical experience Later clinical experience points in the same direction. Retrospective and review-level summaries report Boswellia use for **radiation-related cerebral oedema** and **radiation necrosis**, usually in the range of about **3,600 to 4,500 mg/day** in divided doses. That range is important because it shows the glioblastoma and brain-tumour literature does **not** revolve around low supplement-label dosing. It usually discusses **higher supervised dosing** when the goal is oedema control after brain radiation. ### Very high-dose case experience A 2024 abstract described two patients who accidentally took about **42,000 mg/day** rather than **4,200 mg/day** for radiation-related cerebral oedema. Both reportedly had marked MRI improvement and the dose was surprisingly tolerated, with only mild dysphonia reported in one case. That is **not** a dosing recommendation. It does **not** establish an optimal dose. It only shows that the upper tolerability boundary may be wider than many readers expect. {% hint style="warning" %} The accidental **42,000 mg/day** case experience is not a protocol. It should be treated as an anecdotal safety signal, not as a target dose. {% endhint %} ### Preclinical glioblastoma evidence The tumour-directed side of the Boswellia story is also real. Key themes include: * **AKBA** inhibits growth in multiple glioblastoma cell lines * AKBA shows activity against **glioblastoma stem-like cells** * combined **AKBA plus radiation** suppresses tumour growth more strongly than radiation alone in preclinical work * apoptosis, cell-cycle disruption, and survival-pathway suppression are all reported This does not prove clinical anti-glioblastoma efficacy. It does explain why Boswellia keeps coming up in glioblastoma discussions rather than only in supportive-care conversations. ### Why Boswellia stands out in neuro-oncology Most natural compounds discussed in brain tumours fail at least one of these tests: * weak human data * weak CNS relevance * no clear practical role during radiotherapy Boswellia is unusual because it clears all three. Its strongest current use case is still **oedema support**, not primary tumour control. But the same compound also has credible preclinical tumour biology behind it. That overlap is rare. ### Clinical positioning Boswellia is best viewed here as an **investigational adjunct** with two main roles: 1. **supportive neuro-oncology use** for radiation-related oedema and steroid-sparing discussion 2. **mechanism-based adjunctive interest** because of radiosensitising and anti-glioblastoma preclinical findings This is why glioblastoma and brain tumours remain the strongest practical entry point for Boswellia in oncology. ### Dosing relevance The brain-tumour literature usually discusses doses around **3,600 to 4,500 mg/day** in divided doses. The clearest pilot-trial anchor is **4,200 mg/day**. For the full dosing breakdown, including AKBA comparison logic, see [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/dosing-and-timing.md). ### Key References Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors\ Combined AKBA and radiation treatment inhibited glioblastoma\ New Approach for Enhancing Survival in Glioblastoma\ Boswellia serrata for cerebral radiation necrosis after radiosurgery for brain metastases\ ### Jump to another Boswellia page **Core pages** * [Boswellia in Oncology Overview](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-in-oncology-overview.md) * [Evidence Summary](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/evidence-summary.md) * [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/anticancer-mechanisms.md) * [Boswellia Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type.md) **Mechanism deep dives** * [Redox Dual Action](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/redox-dual-action.md) * [NRF2 Impact](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/nrf2-impact.md) * [Ferroptosis Findings](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/ferroptosis-findings.md) * [Immune Effects](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/immune-effects.md) **Practical pages** * [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/pharmacokinetics-and-metabolism.md) * [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/safety-and-interactions.md) * [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/synergistic-combinations.md) * [Hydroxychloroquine + Boswellia](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/hydroxychloroquine-+-boswellia.md) * [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/dosing-and-timing.md) * [Sourcing Quality Boswellia](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/sourcing-quality-boswellia.md) **Cancer-type pages** * [Glioblastoma & Brain Tumours](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/glioblastoma-and-brain-tumours.md) * [Breast Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/breast-cancer.md) * [Colorectal Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/colorectal-cancer.md) * [Pancreatic Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/pancreatic-cancer.md) * [Prostate Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/prostate-cancer.md) * [Non-Small Cell Lung Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/non-small-cell-lung-cancer.md) * [Ovarian Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/ovarian-cancer.md) * [Other Cancer Types](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/other-cancer-types.md) {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/glioblastoma-and-brain-tumours.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.